41. Blagosklonny MV, An WG, Romanova LY, Trepel J, Fojo T,Neckers L. p53 inhibits hypoxia-inducible factor-stimulatedtranscription. J Biol Chem 1998;273:11995-8.

42. Ambs S, Merriam WG, Ogonfusira MO, Bennett WP, IshibeN, Hussain SP, et al. P53 and vascular endothelial growthfactor regulate tumor growth of NOS2-expressing humancarcinoma cells. Nat Med 1998;12:1371-6.

43. Glockzin S, von Knethen A, Scheffner M, Brune B.Activation of the cell death program by nitric oxideinvolves inhibition of the proteasome. J Biol Chem 1999;274:19581-6.

44. Mannick JB, Miao XQ, Stamler JS. Nitric oxide inhibitsAPO-1/Fas-mediated cell death. J Biol Chem 1997;272:24125-8.

45. Kolb JP. Mechanisms involved in the pro- and anti-apoptoticrole of NO in human leukemia. Leukemia 2000;14:1685-94.

46. Liu L, Stamler JS. NO: an inhibitor of cell death. Cell DeathDiffer 1999;6:937-42.

47. Genaro AM, Hortelano S, Alvarez A, Martinez C, Bosca L.Splenic B lymphocyte programmed cell death is preventedby nitric oxide release through mechanisms involving sus-tained bcl-2 levels. J Clin Invest 1995;95:1884-90.

48. Zhao H, Dugas N, Mathiot C, Delmer A, Dugas B, SigauxF, et al. B-cell chronic lymphocytic leukemia cells express afunctional inducible nitric oxide synthase displaying anti-apoptotic activity. Blood 1998;92:1031-43.

49. Shami PJ, Weimberg JB. Differential effects of nitric oxideon erythroid and myeloid colony growth from CD34+ humanbone marrow cells. Blood 1996;7:977-82.

50. Weinberg JB. Nitric oxide production and nitric oxide syn-thase type 2 expression by human mononuclear phagocytes:a review. Mol Med 1998;4:557-91.

51. Dugas B, Mossalayi DM, Damais C, Kolb JP. Nitric oxideproduction by human monocytes. Evidence for a role ofCD23. Immunol Today 1995;16:574-80.

52. Van’t Hof RJ, Armour KJ, Smith LM, Armour KE, Wei XQ,Liew FY, et al. Requirement of the inducible nitric oxide syn-thase pathway for IL-1-induced osteoclastic bone resorption.Proc Natl Acad Sci USA 2000;97:7993-8.

53. Punjabi CJ, Laskin DL, Heck DE, Laskin JD. Production ofnitric oxide by murine bone marrow cells: inverse corre-lation with cellular proliferation. J Immunol 1992;199:2179-84.

54. Reykdal S, Abboud C, Liesveld J. Effect of nitric oxide pro-duction and oxygen tension on progenitor preservation in exvivo culture. Exp Hematol 1999;27:441-50.

55. Battimelli E, Loscalzo J. Nitric oxide induces apoptosis inmegakaryocytic cell lines. Blood 2000;95:3451-9.

56. Kitagawa M, Takahashi M, Yamaguchi S, Inoue M, OgawaS, Hirokawa K, et al. Expression of inducible nitric oxidesynthase (NOS) in bone marrow cells of myelodysplasticsyndromes. Leukemia 1999;13:699-703.

57. Kim HJ, Chung IJ, Park MR, Lee JJ. Increased nitric oxideand inducible nitric oxide synthase in bone marrow of aplas-tic anemia. Blood 2000;96:924a.

58. Buzard GS, Kasprzak KS. Possible roles of nitric oxide andredox cell signaling in metal-induced toxicity and carcino-genesis: a review. J Environ Pathol Toxicol Oncol 2000;19:179-99.

230 EditorialJ Lab Clin Med

April 2001

CORRECTION

In the article by Brown et al in the January 2001 issue of the Journal (J Lab Clin Med 2001;137:5-13), thearticle contained several errors, as follows: On page 9, paragraph 2, line 2, “equal to 10 IU” should haveread “equal to 1 IU.” On the same page and paragraph, line 6, “the 100 IU (or 10 LD50)” should have read“the 100 IU or (or 100 LD50).” On the same page and paragraph, line 8, “a concentration of 100 fg/100µL” should have read “a concentration of 1 pg/100 µL.” On the same page and paragraph, lines 9 and 10,“tests, 10 fg/10 µL” should have read “tests, 100 fg/10 µL.” On the same page and paragraph, line 11, “and1 ag/nL” should have read “and 10 ag/nL.” On page 9, in the footnote below the left column, line 2, “ani-mal), 1 LD50” should have read “animal), 20 LD50.” In the same footnote, line 6, “represents a higher con-centration” should have read “represents a lower concentration.” In the same footnote, line 9, “equivalentto 10 IU” should have read “equivalent to 0.5 IU.”